Lactobacillus plantarum 299v Probiotic for Diabetic Macular Edema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, prospective, open-label study testing Lactobacillus plantarum 299v as an oral supplement for adults with diabetic macular edema. Participants in two groups receive the probiotic for four months and undergo eye imaging and vision testing at 1–4 months, with tracking of anti-VEGF injections. Outcomes compare changes in central macular thickness and visual acuity to historical data. The study evaluates whether the probiotic could reduce treatment burden or improve eye structure and function. Eligibility includes adults with DME, while contraindications include probiotic intolerance or immunocompromised status.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age of at least 18 years, presence of DME at the current clinical visit

Exclusion Criteria:

* Patients with contraindication to probiotic supplement (e.g. prior allergy or GI intolerance and any type of immunocompromised diseases).

Where it's running

• Mass Eye and Ear
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Demetrios G. Vavvas, MD PhD
• Email: Demetrios_Vavvas@meei.harvard.edu
• Phone: 6175736874

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• Testing Different Doses of BI 3812465 in Diabetic Macular Edema

  Researchers are testing whether varying doses of BI 3812465 can be tolerated in adults with center-involved diabetic macular edema.

  Recruiting at 26 sites Phase 1/2 Boehringer Ingelheim · Phoenix, Arizona and 28 other locations · NCT07553429

• Comparing AVT29 and Eylea HD for diabetic macular edema

  This study will test whether AVT29 works as well and is as safe as Eylea HD in adults with center-involving diabetic macular edema who have reduced vision.

  Recruiting Phase 3 Alvotech Swiss AG · Budapest · NCT07489131

• Daily oral Kamuvudine-9 (K9) for diabetic macular edema

  This trial will test whether taking oral K9 twice daily is safe and improves vision in adults with diabetic macular edema.

  Recruiting Phase 1/2 Vistar Eye Center · Roanoke, Virginia · NCT07458061

• RO7823653 injections, alone or with faricimab, for diabetic macular edema

  This research tests injections of RO7823653, given alone or with faricimab, in people with diabetic macular edema to see if the medication is safe and how the eye handles it.

  Recruiting at 12 sites Phase 1 Genentech, Inc. · Peoria, Arizona and 11 other locations · NCT07425522

• Early progression of non-center diabetic macular edema after phacoemulsification

  This will see if non-center-involving diabetic macular edema worsens in the early weeks after cataract surgery in adults with diabetes.

  Recruiting Ain Shams University · Cairo · NCT07038967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.